NetScientific PLC (AIM:NSCI) has acquired a 30% stake in Vortex Biotech Holdings, a company it used to own. The difference now, as the company’s chief executive, Ilian Iliev explains, is that Vortex has been substantially derisked as an investment.
Vortex is an innovative transatlantic company that has “a world-leading mature technology” that can capture undamaged circulating tumour cells that can then be used for follow-on analysis.
“This space is growing really, really rapidly … and Vortex is right in the middle of it,” the NetScientific CEO told Proactive.